Radioimmunotherapy of Colorectal Cancer in Small Volume Disease: Preclinical Evaluation in Comparison to Equitoxic Chemotherapy and Preliminary Results of an Ongoing Phase-I/II Clinical Trial
The aim of the present study was to compare, in preclinical models, the therapeutic efficacy of radioimmunotherapy in colorectal cancer to equitoxic chemotherapy, as well as to evaluate, in a pilot clinical trial, their efficacy in small volume disease. The data suggest that radioimmunotherapy may be a viable therapeutic option in colorectal cancer patients with limited disease. Myelotoxicity is the only dose-limiting organ toxicity. Although most patients were treated below the maximum tolerated dose, encouraging anti-tumor effects have been observed.
KeywordsNude Mouse Maximum Tolerate Dose Colorectal Cancer Patient Tumor Cell Inoculation Pilot Clinical Trial
Unable to display preview. Download preview PDF.
- 1.DeVita VT, Hellman S, Rosenberg SA (eds.): Cancer — Principles and Practice of Oncology (5th edition). Philadelphia: Lippincott-Raven, 1997.Google Scholar
- 5.Behr TM, Sgouros G, Vougioukas V, Memtsoudis S, Gratz S, Nebendahl K, Schmidberger H, Becker W: Therapeutic efficacy and dose-limiting toxicity of Auger-electron versus beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125i-versus 131I-labeled CO17-1A in a colorectal cancer model. Int J Cancer: in press, 1998.Google Scholar
- 6.Behr TM, Sgouros G, Sharkey RM, Dunn RM, Blumenthal RD, Kolbert K, Juweid ME, Siegel JA, Goldenberg DM: 90Y-Dosimetry in the nude mouse: evaluation of three dosimetry models in relation to the observed biological effects in the radioimmunotherapy of human colon cancer xenografts. Proc 6th Int Radiopharm Dosim Symp Gatlinburg (TN) 1996, in press: 1997.Google Scholar
- 11.Behr TM, Wulst E, Radetzky S, Blumenthal RD, Dunn RM, Gratz S, Rave-Fränk M, Schmidberger H, Raue F, Becker W: Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 57: 5309–5319, 1997.PubMedGoogle Scholar